The DRG has a high sensory nerve density, and due its location on the way from the lower limbs toward the brain it is a promising target for neurostimulation.
St. Jude already has 59 clinical centers and more than 300 physicians lined up to begin implanting the device.
From St. Jude:
Initial results from the ACCURATE IDE study, the largest study to date evaluating patients suffering from neuropathic Chronic intractable pain associated with CRPS I and II or peripheral causalgia (PC), showed DRG stimulation provided patients with superior pain relief over traditional tonic SCS. Approval of DRG stimulation with the St. Jude Medical Axium Neurostimulator System was based in part on the results of this study in which patients were randomized to receive either DRG stimulation delivered by the Axium Neurostimulator system or traditional tonic SCS therapy delivered by a competitor’s system.
04-11-2016, 09:38 PM
St. Jude’s Axium Dorsal Root Ganglion Neurostimulator Launched in U.S. for Chronic Pa
St. Jude Medical is releasing in the United States its Axium Dorsal Root Ganglion (DRG) Neurostimulator for people with Chronic pain from complex regional pain syndrome I and II for whom traditional neurostimulation is **t sufficiently effective.
العرض الشجري